Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03158805 · ClinicalTrials.gov registry record · Phase 2
Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)
A Phase 2 study, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT03158805 is a Phase 2 study that has completed, run by Lindner Center of HOPE. The registered enrollment target is 60 participants.
The verdict
NCT03158805, a Phase 2 study, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc injection will display greater efficacy as compared to placebo in decreasing body weight in patients with BP who are obese or overweight. To prove this hypothesis, investigators will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP. The investigators have chosen BP rather than another SMI because it is the most common SMI (more common than schizophrenia or schizoaffective disorder) and has a particularly strong association with obesity.
Interventions
- OTHER Placebo
- DRUG LIRAGLUTIDE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2023-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03158805
The ClinicalTrials.gov registry entry for NCT03158805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03158805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03158805 about?
NCT03158805 is a clinical study titled "Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)". Taken together these data support the hypothesis that liraglutide 3.0 mg sc injection will reduce body weight and improve metabolic variables in obese or overweight patients with BP without worsening psychiatric symptoms. The investigators predict that liraglutide 3.0 mg sc injection will display gr...
What is the current status of trial NCT03158805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2017-04-26. Estimated completion is 2023-01-01.
What interventions are being tested in trial NCT03158805?
The interventions under investigation include: Placebo (OTHER), LIRAGLUTIDE (DRUG).
Who is sponsoring clinical trial NCT03158805?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.